TuHURA Biosciences (NASDAQ:HURA) Stock Keeps Buy Rating at HC Wainwright

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright‘s price target suggests a potential upside of 373.93% from the stock’s current price.

HURA has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Citizens Jmp reiterated a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Stock Performance

TuHURA Biosciences stock traded up $0.07 during midday trading on Tuesday, reaching $2.11. 396,899 shares of the company’s stock were exchanged, compared to its average volume of 876,430. TuHURA Biosciences has a 52 week low of $0.41 and a 52 week high of $3.43. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18. The firm has a market cap of $134.47 million, a price-to-earnings ratio of -3.91 and a beta of -0.21. The stock’s 50-day simple moving average is $2.04 and its 200 day simple moving average is $1.93.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. On average, analysts expect that TuHURA Biosciences will post -0.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TuHURA Biosciences

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of TuHURA Biosciences during the second quarter worth approximately $1,615,000. Merck & Co. Inc. bought a new stake in shares of TuHURA Biosciences during the second quarter worth approximately $45,501. Invst LLC bought a new stake in shares of TuHURA Biosciences during the second quarter worth approximately $99,000. Bank of America Corp DE bought a new stake in shares of TuHURA Biosciences during the second quarter worth approximately $99,000. Finally, Squarepoint Ops LLC bought a new stake in shares of TuHURA Biosciences during the second quarter worth approximately $81,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.